CAMP and histiocytic sarcoma: Additional studies have found the progression of HS severity to be correlated with increased levels of these pro-inflammatory cytokines promoted by LL-37, including IL-17 and TNF-α (46, 88–90), suggesting the potential therapeutic targeting of LL-37.